Literature DB >> 33521591

Heat inactivation of the severe acute respiratory syndrome coronavirus 2.

Christophe Batéjat1, Quentin Grassin1, Jean-Claude Manuguerra1, India Leclercq1,2.   

Abstract

Cell culture medium, nasopharyngeal and sera samples spiked with SARS-CoV-2 were subjected to heat inactivation for various periods of time, ranging from 30 s to 60 min. Our results showed that SARS-CoV-2 could be inactivated in less than 30 min, 15 min, and 3 min at 56 °C, 65 °C, and 95 °C, respectively. These data could help laboratory workers to improve their protocols by handling the virus in biosafety conditions.
© 2021 Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

Entities:  

Keywords:  Covid-19; Heat; Inactivation; SARS-CoV-2

Year:  2021        PMID: 33521591      PMCID: PMC7825878          DOI: 10.1016/j.jobb.2020.12.001

Source DB:  PubMed          Journal:  J Biosaf Biosecur        ISSN: 2588-9338


In December 2019, a new coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan City, Hubei Province in China and quickly became pandemic, spreading to almost all countries in about 2 months. This highly contagious virus has already caused a great number of infections and deaths, and the scientific community is facing new challenges to combat the ongoing outbreak. As no specific therapeutics and vaccines are available for disease control, lockdowns, social distancing, and quick detection of cases are currently the main weapons against the virus. Diagnostic and serological tools help to detect SARS-CoV-2 carriers and immunized recovered patients as soon as possible, and are therefore part of this fighting strategy and necessary to consider a return to normal life. In this context, viral inactivation procedures are urgently needed to allow safe experimental laboratory conditions. Amplification of viral RNA by quantitative RT-PCR is currently the gold standard procedure for diagnosis recommended by the World Health Organization. Viral RNA extraction kits sometimes require an initial lysis step at 70 °C or more for 5 min. Heat inactivation of the virus is also needed for serum treatment before ELISA and serological assays. Although 56 °C is commonly used for inactivation of enveloped viruses,2, 3 higher temperatures can be used in some cases.4, 5, 6 This temperature is also used to eliminate serum complement. In this study, we exposed SARS-CoV-2 to three different inactivation temperatures (56 °C, 65 °C, and 95 °C) for various periods of time and tested its infectivity using the TCID50 method. A human strain of SARS-CoV-2, isolated from a French patient hospitalized in February 2020 (GISAID accession number: EPI_ISL_437689), was grown on Vero E6 cells for three passages. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM 1X, GIBCO) supplemented with 5% fetal calf serum (FCS) and antibiotics (0.1 units penicillin, 0.1 mg/mL streptomycin, GIBCO) at 37 °C in a humidified 5% CO2 incubator. The SARS-CoV-2 virus was titrated by the TCID50 method, as described previously, except that Vero E6 cells were used and examination for cytopathic effect was performed after 5 days. The viral titer was adjusted from 6.5 log10 TCID50/mL to a final titer of 6 log10 TCID50/mL in three different kinds of media, that is, cell culture medium (DMEM 1X), pooled nasopharyngeal samples of several patients tested negative for SARS-CoV-2, and pooled sera from donors collected before the 1st of January 2020 at a time when the virus was not circulating in France. Diluted samples (500 µL) were submitted in triplicate to various temperatures for different periods of time in a calibrated and verified dry water bath, cooled on ice, and tested for infectivity by the TCID50 method as described above. All experiments were conducted under strict BSL3 conditions. The mean viral titers obtained for each condition are presented in Table 1, Table 2, Table 3 . Viral inactivation over time is shown in Fig. 1 .
Table 1

Log10 TCID50 per mL titers obtained after inactivation of cell culture medium containing 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml).

56 °C

65 °C
Time (min)0153038600153060
Cell culture medium6.63.23NDNDND6.6NDNDND
Table 2

Log10 TCID50 per mL titers obtained after inactivation of nasopharyngeal samples spiked with 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml).

56 °C

65 °C
95 °C
Time (min)010203005101500.536
Nasopharyngeal samples6.172.77NDND6.574.83NDND6.576.23NDND
Table 3

Log10 TCID50 per mL titers obtained after inactivation of human sera spiked with 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml).

56 °C
Time (min)0510152030
Sera6.24.872.57NDNDND
Fig. 1

Viral titers in log10 TCID50/mL obtained after heat inactivation of infected cell culture medium (A), nasopharyngeal samples spiked with SARS-CoV-2 (B), and sera samples from negative donors spiked with SARS-CoV-2 (C). Each condition was performed in triplicate. Each dot represents the mean viral titer and vertical lines represent the standard deviation.

Log10 TCID50 per mL titers obtained after inactivation of cell culture medium containing 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml). Log10 TCID50 per mL titers obtained after inactivation of nasopharyngeal samples spiked with 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml). Log10 TCID50 per mL titers obtained after inactivation of human sera spiked with 6 log10 TCID50/mL of SARS-CoV-2. ND: not detected (below the limit of virus detection which corresponded to 0.67 log10 TCID50 per ml). Viral titers in log10 TCID50/mL obtained after heat inactivation of infected cell culture medium (A), nasopharyngeal samples spiked with SARS-CoV-2 (B), and sera samples from negative donors spiked with SARS-CoV-2 (C). Each condition was performed in triplicate. Each dot represents the mean viral titer and vertical lines represent the standard deviation. At 56 °C, no infectious virus was detected within 30 min in cell culture medium (Fig. 1A) and within 20 min in nasopharyngeal samples and sera (Fig. 1B and 1C). As expected, increasing the temperature had a negative effect on viral infectivity as no infectious virus was detected within 15 min at 65 °C (Fig. 1A and 1B). At 95 °C, 3 min was sufficient to inactivate the virus in nasopharyngeal samples (Fig. 1B). The high quantity of infectious virus detected after 30 s (6.23 log10 TCID50/mL) was probably due to the time necessary for the media and the tubes to reach 95 °C inside. To complement our results, viral RNA from each sample, except from nasopharyngeal samples treated at 56 °C, was extracted using a Nucleospin RNA Virus kit (Macherey-Nagel) for quantitative RT-PCR. Primers and probes targeting two regions of the RdRP gene developed by the French National Reference Center for Respiratory Infections Viruses and a LightCycler 480 II instrument were used as previously described. The E gene was used as a tertiary target for confirmation, following the Charité protocol. The results showed that the mean genomic RNA copy number ranged between 9.9 × 107 copy genome/5 µL and 5.3 × 109 copy genome/5 µL (data not shown). For each condition, the quantity of viral RNA was very stable over time, suggesting that viral RNA remained intact in virus particles. At 95 °C, the results showed a slight decrease in viral RNA quantity over time with approximately a 2.2-fold increase in the cq value, which could potentially prevent SARS-CoV-2 detection in samples with low viral loads.10, 11 These results are similar to our previous results obtained with the Middle East Respiratory Syndrome coronavirus (MERS-CoV), which belongs to the same genus of viruses. In conclusion, SARS-CoV-2 is relatively sensitive to heat inactivation under our laboratory conditions. These data can help laboratory workers to elaborate and improve their protocols for SARS-CoV-2 experiments, and reinforce our current knowledge on coronavirus survival.12, 13

CRediT authorship contribution statement

Christophe Batéjat: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing - review & editing. Quentin Grassin: Investigation. Jean-Claude Manuguerra: Resources, Writing - review & editing. India Leclercq: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing - original draft, Writing - review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  11 in total

1.  Virus-specific thermostability and heat inactivation profiles of alphaviruses.

Authors:  So Lee Park; Yan-Jang S Huang; Wei-Wen Hsu; Susan M Hettenbach; Stephen Higgs; Dana L Vanlandingham
Journal:  J Virol Methods       Date:  2016-04-11       Impact factor: 2.014

Review 2.  Survival and inactivation of classical swine fever virus.

Authors:  S Edwards
Journal:  Vet Microbiol       Date:  2000-04-13       Impact factor: 3.293

3.  Inactivation of Zaire ebolavirus Variant Makona in Human Serum Samples Analyzed by Enzyme-Linked Immunosorbent Assay.

Authors:  Todd Cutts; Allen Grolla; Shane Jones; Bradley W M Cook; Xiangguo Qiu; Steven S Theriault
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

4.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

5.  Persistence of the 2009 pandemic influenza A (H1N1) virus in water and on non-porous surface.

Authors:  Amélie Dublineau; Christophe Batéjat; Anthony Pinon; Ana Maria Burguière; India Leclercq; Jean-Claude Manuguerra
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

6.  Viral load of SARS-CoV-2 in clinical samples.

Authors:  Yang Pan; Daitao Zhang; Peng Yang; Leo L M Poon; Quanyi Wang
Journal:  Lancet Infect Dis       Date:  2020-02-24       Impact factor: 25.071

7.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

8.  Heat inactivation of the Middle East respiratory syndrome coronavirus.

Authors:  India Leclercq; Christophe Batéjat; Ana M Burguière; Jean-Claude Manuguerra
Journal:  Influenza Other Respir Viruses       Date:  2014-07-29       Impact factor: 4.380

9.  Stability of SARS-CoV-2 in different environmental conditions.

Authors:  Alex W H Chin; Julie T S Chu; Mahen R A Perera; Kenrie P Y Hui; Hui-Ling Yen; Michael C W Chan; Malik Peiris; Leo L M Poon
Journal:  Lancet Microbe       Date:  2020-04-02

10.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Authors:  Neeltje van Doremalen; Trenton Bushmaker; Dylan H Morris; Myndi G Holbrook; Amandine Gamble; Brandi N Williamson; Azaibi Tamin; Jennifer L Harcourt; Natalie J Thornburg; Susan I Gerber; James O Lloyd-Smith; Emmie de Wit; Vincent J Munster
Journal:  N Engl J Med       Date:  2020-03-17       Impact factor: 91.245

View more
  35 in total

1.  Small form factor flow virometer for SARS-CoV-2.

Authors:  Rubaiya Hussain; Alfredo E Ongaro; Maria L Rodriguez de la Concepción; Ewelina Wajs; Eva Riveira-Muñoz; Ester Ballana; Julià Blanco; Ruth Toledo; Anna Chamorro; Marta Massanella; Lourdes Mateu; Eulalia Grau; Bonaventura Clotet; Jorge Carrillo; Valerio Pruneri
Journal:  Biomed Opt Express       Date:  2022-02-22       Impact factor: 3.732

2.  SARS-CoV-2 RNA detected in urban wastewater from Porto, Portugal: Method optimization and continuous 25-week monitoring.

Authors:  Maria Paola Tomasino; Miguel Semedo; Pedro Vieira E Moreira; Elza Ferraz; Adelaide Rocha; Maria F Carvalho; Catarina Magalhães; Ana P Mucha
Journal:  Sci Total Environ       Date:  2021-06-17       Impact factor: 7.963

3.  Mitigation of SARS-CoV-2 transmission at a large public university.

Authors:  Diana Rose E Ranoa; Robin L Holland; Fadi G Alnaji; Kelsie J Green; Leyi Wang; Richard L Fredrickson; Tong Wang; George N Wong; Johnny Uelmen; Sergei Maslov; Zachary J Weiner; Alexei V Tkachenko; Hantao Zhang; Zhiru Liu; Ahmed Ibrahim; Sanjay J Patel; John M Paul; Nickolas P Vance; Joseph G Gulick; Sandeep Puthanveetil Satheesan; Isaac J Galvan; Andrew Miller; Joseph Grohens; Todd J Nelson; Mary P Stevens; P Mark Hennessy; Robert C Parker; Edward Santos; Charles Brackett; Julie D Steinman; Melvin R Fenner; Kirstin Dohrer; Michael DeLorenzo; Laura Wilhelm-Barr; Brian R Brauer; Catherine Best-Popescu; Gary Durack; Nathan Wetter; David M Kranz; Jessica Breitbarth; Charlie Simpson; Julie A Pryde; Robin N Kaler; Chris Harris; Allison C Vance; Jodi L Silotto; Mark Johnson; Enrique Andres Valera; Patricia K Anton; Lowa Mwilambwe; Stephen P Bryan; Deborah S Stone; Danita B Young; Wanda E Ward; John Lantz; John A Vozenilek; Rashid Bashir; Jeffrey S Moore; Mayank Garg; Julian C Cooper; Gillian Snyder; Michelle H Lore; Dustin L Yocum; Neal J Cohen; Jan E Novakofski; Melanie J Loots; Randy L Ballard; Mark Band; Kayla M Banks; Joseph D Barnes; Iuliana Bentea; Jessica Black; Jeremy Busch; Abigail Conte; Madison Conte; Michael Curry; Jennifer Eardley; April Edwards; Therese Eggett; Judes Fleurimont; Delaney Foster; Bruce W Fouke; Nicholas Gallagher; Nicole Gastala; Scott A Genung; Declan Glueck; Brittani Gray; Andrew Greta; Robert M Healy; Ashley Hetrick; Arianna A Holterman; Nahed Ismail; Ian Jasenof; Patrick Kelly; Aaron Kielbasa; Teresa Kiesel; Lorenzo M Kindle; Rhonda L Lipking; Yukari C Manabe; Jade Mayes; Reubin McGuffin; Kenton G McHenry; Agha Mirza; Jada Moseley; Heba H Mostafa; Melody Mumford; Kathleen Munoz; Arika D Murray; Moira Nolan; Nil A Parikh; Andrew Pekosz; Janna Pflugmacher; Janise M Phillips; Collin Pitts; Mark C Potter; James Quisenberry; Janelle Rear; Matthew L Robinson; Edith Rosillo; Leslie N Rye; MaryEllen Sherwood; Anna Simon; Jamie M Singson; Carly Skadden; Tina H Skelton; Charlie Smith; Mary Stech; Ryan Thomas; Matthew A Tomaszewski; Erika A Tyburski; Scott Vanwingerden; Evette Vlach; Ronald S Watkins; Karriem Watson; Karen C White; Timothy L Killeen; Robert J Jones; Andreas C Cangellaris; Susan A Martinis; Awais Vaid; Christopher B Brooke; Joseph T Walsh; Ahmed Elbanna; William C Sullivan; Rebecca L Smith; Nigel Goldenfeld; Timothy M Fan; Paul J Hergenrother; Martin D Burke
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

4.  Performance evaluation of a non-invasive one-step multiplex RT-qPCR assay for detection of SARS-CoV-2 direct from saliva.

Authors:  Chris Denning; Andrew V Benest; Claire Seedhouse; Harry H Jenkins; Ana A Tellechea Lopez; Francesco Saverio Tarantini; Hannah Tomlin; Danielle Scales; I-Ning Lee; Siyu Wu; Ralph Hyde; Katarzyna Lis-Slimak; Timothy Byaruhanga; Jamie L Thompson; Sara Pijuan-Galito; Lara Doolan; Kazuyo Kaneko; Penny Gwynne; Caroline Reffin; Emily Park; Jayasree Dey; Jack Hill; Asta Arendt-Tranholm; Amy Stroud; Moira Petrie
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

5.  Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance.

Authors:  Shimaa S El-Malah; Jayaprakash Saththasivam; Khadeeja Abdul Jabbar; Arun K K; Tricia A Gomez; Ayeda A Ahmed; Yasmin A Mohamoud; Joel A Malek; Laith J Abu Raddad; Hussein A Abu Halaweh; Roberto Bertollini; Jenny Lawler; Khaled A Mahmoud
Journal:  Environ Technol Innov       Date:  2022-06-22

6.  Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.

Authors:  Achim Thomzig; Katja Wagenführ; Phillip Pinder; Marion Joncic; Walter J Schulz-Schaeffer; Michael Beekes
Journal:  Acta Neuropathol       Date:  2021-04-24       Impact factor: 17.088

7.  A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein.

Authors:  Julia Hambach; Tobias Stähler; Thomas Eden; Dorte Wendt; Natalie Tode; Friedrich Haag; Eva Tolosa; Marcus Altfeld; Anahita Fathi; Christine Dahlke; Marylyn M Addo; Stephan Menzel; Friedrich Koch-Nolte
Journal:  Immun Inflamm Dis       Date:  2021-05-12

Review 8.  Monitoring COVID-19 through SARS-CoV-2 quantification in wastewater: progress, challenges and prospects.

Authors:  José Alhama; Juan P Maestre; M Ángeles Martín; Carmen Michán
Journal:  Microb Biotechnol       Date:  2021-12-14       Impact factor: 6.575

9.  Survival of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Herpes Simplex Virus 1 (HSV-1) on Foods Stored at Refrigerated Temperature.

Authors:  Janak Dhakal; Mo Jia; Jonathan D Joyce; Greyson A Moore; Reza Ovissipour; Andrea S Bertke
Journal:  Foods       Date:  2021-05-04

10.  Rapid determination of infectious SARS-CoV-2 in PCR-positive samples by SDS-PMA assisted RT-qPCR.

Authors:  Wei Hong; Jin Xiong; Raphael Nyaruaba; Junhua Li; Elishiba Muturi; Huan Liu; Junping Yu; Hang Yang; Hongping Wei
Journal:  Sci Total Environ       Date:  2021-07-17       Impact factor: 7.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.